Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 10/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958891 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29524384 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL28525054 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29390151 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL958888 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29523882 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL3740313 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL13388428 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL19464901 | 0.93 | ADORA3 (0.87) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL20122154 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572790-A2 | PHLIP®-MEDIATED DELIVERY OF STING AGONISTS | University of Rhode Island Board of Trustees (US) | 2025-06-25 | — | — | EP | claimed |
| CN-119730879-A | PHLIP beta-mediated STING agonist delivery | 罗德岛大学理事会 | 2025-03-28 | — | — | CN | claimed |
| WO-2024040027-A2 | PHLIP®-MEDIATED DELIVERY OF STING AGONISTS | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2024-02-22 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | FULGENT GENETICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12397010-B2 | Treatment of chronic headaches | SAINT LOUIS UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114903903-A | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-04-21 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-109310695-B | Compounds and methods for treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | HAO2, HRH1, PHB1 | ADORA3 1003/4885ADORA1 2043/4885ADORA2A 3094/4885 |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | ADORA3 1795/4885ADORA1 2502/4885ADORA2A 2854/4885 |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CD47, PBK, CD4 | ADORA3 2015/4885ADORA1 2436/4885ADORA2A 1144/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20220117985-A1 | TREATMENT OF CHRONIC HEADACHES | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885ADORA1 10/4885ADORA2A 3/4885 |
| US-12397010-B2 | Treatment of chronic headaches | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885ADORA1 10/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.